Amryt Pharma plc (AMYT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Amryt Pharma plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeffrey Gundlach DoubleLine Capital LP | 250,000 | $3.31M | $3.67M | $364,282.16 | 11% |
Amryt Pharma plc (AMYT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amryt Pharma plc ever had a stock split?
Amryt Pharma plc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Joseph A. Wiley CEO | NASDAQ (NGS) Exchange | 03217L106 CUSIP |
| IE Country | 289 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Amryt Pharma plc is a commercial-stage biopharmaceutical company with a clear focus on acquiring, developing, and commercializing treatments that aim to improve the lives of patients suffering from rare and orphan diseases. Founded in 2015 and based in Dublin, Ireland, the company actively markets its products across the Americas, Europe, and the Middle East, demonstrating its global presence and commitment to addressing the needs of patients with limited treatment options.
Products and Services
Amryt Pharma plc's portfolio consists of innovative treatments and promising candidates in development, catered to a spectrum of rare diseases:
- Metreleptin: This adjunct to diet replacement therapy is utilized to treat complications arising from leptin deficiency in patients who suffer from congenital or acquired generalized lipodystrophy. By replacing leptin, metreleptin helps regulate fat metabolism and energy expenditure, crucial for patients afflicted by this rare condition.
- Oral Octreotide: Serving as a long-term maintenance therapy for patients with acromegaly, oral octreotide aids in controlling excessive growth hormone production. This oral formulation offers a significant benefit over traditional injections, providing patients with a less invasive treatment option.
- Lomitapide: Targeted at adults diagnosed with Homozygous Familial Hypercholesterolaemia, lomitapide is an adjunct to a low-fat diet and other lipid-lowering medicinal products. Its role in inhibiting the liver's ability to produce LDL cholesterol addresses a critical need in managing this life-threatening genetic disorder.
In addition to these commercial-stage products, Amryt Pharma is investing in the future of rare disease treatment with development candidates such as:
- Oleogel-S10: Dedicated to treating the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a painful and distressing genetic skin disorder. Oleogel-S10 aims to facilitate wound healing in patients suffering from this debilitating condition.
- AP103: A pre-clinical gene therapy candidate for patients with dystrophic EB. By focusing on the genetic roots of the disease, AP103 represents hope for a more definitive treatment option for those affected by EB.
